Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors
Open Access
- 24 June 2022
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (26)
Abstract
Tumor infiltration by T cells profoundly affects cancer progression and responses to immunotherapy. However, the tumor immunosuppressive microenvironment can impair the induction, trafficking, and local activity of antitumor T cells. Here, we investigated whether intratumoral injection of virus-derived peptide epitopes could activate preexisting antiviral T cell responses locally and promote antitumor responses or antigen spreading. We focused on a mouse model of cytomegalovirus (CMV), a highly prevalent human infection that induces vigorous and durable T cell responses. Mice persistently infected with murine CMV (MCMV) were challenged with lung (TC-1), colon (MC-38), or melanoma (B16-F10) tumor cells. Intratumoral injection of MCMV-derived T cell epitopes triggered in situ and systemic expansion of their cognate, MCMV-specific CD4 + or CD8 + T cells. The MCMV CD8 + T cell epitopes injected alone provoked arrest of tumor growth and some durable remissions. Intratumoral injection of MCMV CD4 + T cell epitopes with polyinosinic acid:polycytidylic acid (pI:C) preferentially elicited tumor antigen–specific CD8 + T cells, promoted tumor clearance, and conferred long-term protection against tumor rechallenge. Notably, secondary proliferation of MCMV-specific CD8 + T cells correlated with better tumor control. Importantly, intratumoral injection of MCMV-derived CD8 + T cell–peptide epitopes alone or CD4 + T cell–peptide epitopes with pI:C induced potent adaptive and innate immune activation of the tumor microenvironment. Thus, CMV-derived peptide epitopes, delivered intratumorally, act as cytotoxic and immunotherapeutic agents to promote immediate tumor control and long-term antitumor immunity that could be used as a stand-alone therapy. The tumor antigen–agnostic nature of this approach makes it applicable across a broad range of solid tumors regardless of their origin.Keywords
Funding Information
- NIH (INTRAMURAL PROGRAM)
This publication has 60 references indexed in Scilit:
- Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding ToxicityClinical Cancer Research, 2013
- Aging predisposes to acute inflammatory induced pathology after tumor immunotherapyJournal of Experimental Medicine, 2013
- Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+T-Cell Response in Allogeneic Stem Cell Transplant RecipientsClinical and Vaccine Immunology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceCancer Immunology, Immunotherapy, 2011
- QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunityExpert Review of Molecular Diagnostics, 2011
- Review of cytomegalovirus seroprevalence and demographic characteristics associated with infectionReviews in Medical Virology, 2010
- Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA VaccinationClinical Cancer Research, 2008
- Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8 + memory T cell subsetsProceedings of the National Academy of Sciences, 2004
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986